Hoppa till innehållet

OMXSPI+1,07%

S&P 500+0,37%

FTSE 100+0,10%

DAX+0,31%

NIKKEI+0,73%
Redeye: Vitrolife Q1 update - Entering 2024 with low growth

Vitrolife’s Q1 shows that the headwind for Genetics will likely last until mid-2024. The combined effect from insourcing (PGT-A), ERA and EmbryoMap switching will likely contribute to a considerable headwind in Q2 (ERA could improve). Our updated view is a base case valuation of SEK 220 (245), a Bull Case of SEK 365(400), and a Bear Case of SEK 95 (100).

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vitrolife Q1 update - Entering 2024 with low growth

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera